GLAUKOS CORPORATION

Lobbying for GLAUKOS CORPORATION · Research and product development

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 16, 2026

Expenses

$240,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

H.R. 3514/ S. 1816 Improving Seniors Timely Access to Care Act of 2025 H.R. 2527 Early Detection of Vision Impairments for Children Act of 2025 CMS payment methodologies for OPPS/ASC Medicare administrative contractor coverage determinations Medicare Part B drug payment policies

Bills named in this filing 3

H.R. 3514
Improving Seniors’ Timely Access to Care Act of 2025
S. 1816
Improving Seniors’ Timely Access to Care Act of 2025
H.R. 2527
Early Detection of Vision Impairments for Children Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.